Key Takeaways
- • Renaissance Technologies' flagship Medallion fund delivered a 39% annualized post-fee return between 1988 and 2018, far exceeding Warren Buffett's Berkshire Hathaway (16% annually) and the S&P 500 (10% annually) over the same period.
- • A $1 investment in Medallion in 1988 grew to approximately $27,000 net of fees by end-2018, compared to $107 from Berkshire Hathaway and $20 from the S&P 500, demonstrating sustained outperformance across three decades.
- • Renaissance Technologies, founded by Cold War codebreaker and mathematician Jim Simons, manages approximately $120 billion and employs a quantitative trading strategy that has consistently beaten traditional active managers and passive benchmarks.
- • Renaissance's top ten holdings as of Q3 2019 include Bristol-Myers Squibb, Chipotle Mexican Grill, Verisign, Celgene, Novo Nordisk, Palo Alto Networks, Biogen, and Vertex Pharmaceuticals, with significant exposure to healthcare and technology sectors.
- • Medallion fund remains restricted to Renaissance employees, but its extraordinary track record—66% annualized returns before fees—positions the firm's disclosed holdings as a meaningful reference point for understanding successful institutional capital allocation.
Summary
Renaissance Technologies, the $120 billion hedge fund founded by Jim Simons—a Cold War codebreaker and mathematician—has achieved exceptional long-term performance that materially exceeds both Warren Buffett's Berkshire Hathaway and broad market returns. According to Greg Zuckerman's book "The Man Who Solved The Market: How Jim Simons launched the Quant Revolution," Renaissance's flagship Medallion fund delivered a 39% annualized post-fee return between 1988 and 2018, representing a 66% return before fees. This performance differential compounds dramatically over time: a dollar invested in Medallion in 1988 reached approximately $27,000 net of fees by the end of 2018, dwarfing the $107 return from Berkshire Hathaway and the $20 total return from the S&P 500 benchmark over the identical period.
The performance gap underscores the sustained competitive advantage of Renaissance's quantitative investment methodology. While Berkshire Hathaway averaged approximately 16% annual returns and the S&P 500 delivered 10% annually, Medallion's 39% post-fee return reflects a systematic trading approach that has weathered multiple market cycles, including the 2008 financial crisis and the 2000 technology downturn. Though Medallion restricts investment to Renaissance employees, the fund's disclosed holdings provide institutional investors with insight into the capital allocation patterns of one of the industry's most successful managers.
As of the quarter ended September 30, 2019, Renaissance's ten largest holdings included Bristol-Myers Squibb, Chipotle Mexican Grill, Verisign, Celgene, Novo Nordisk, Palo Alto Networks, Biogen, and Vertex Pharmaceuticals. The portfolio reflects concentration in healthcare and technology sectors, with significant positions in pharmaceutical companies and cybersecurity firms. This sector allocation diverges notably from Berkshire Hathaway's traditional preference for consumer staples, financials, and industrial stocks, highlighting the distinct investment philosophies between quantitative and fundamental value approaches.
The performance gap underscores the sustained competitive advantage of Renaissance's quantitative investment methodology. While Berkshire Hathaway averaged approximately 16% annual returns and the S&P 500 delivered 10% annually, Medallion's 39% post-fee return reflects a systematic trading approach that has weathered multiple market cycles, including the 2008 financial crisis and the 2000 technology downturn. Though Medallion restricts investment to Renaissance employees, the fund's disclosed holdings provide institutional investors with insight into the capital allocation patterns of one of the industry's most successful managers.
As of the quarter ended September 30, 2019, Renaissance's ten largest holdings included Bristol-Myers Squibb, Chipotle Mexican Grill, Verisign, Celgene, Novo Nordisk, Palo Alto Networks, Biogen, and Vertex Pharmaceuticals. The portfolio reflects concentration in healthcare and technology sectors, with significant positions in pharmaceutical companies and cybersecurity firms. This sector allocation diverges notably from Berkshire Hathaway's traditional preference for consumer staples, financials, and industrial stocks, highlighting the distinct investment philosophies between quantitative and fundamental value approaches.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.